Kopran’s wholly owned subsidiary - Kopran Research Laboratories has purchased Maxheal Pharmaceuticals (India), an API facility at Panoli in the state of Gujarat on Slump Sale basis.
The acquired unit will be suitably upgraded and expanded. The expansion of the unit is expected to be completed by December, 2018 to launch new line of products.
Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
